TITLE

Vildagliptin was noninferior to rosiglitazone for glycemic control in type 2 diabetes but caused less weight gain: COMMENTARY

AUTHOR(S)
Montori, Victor M.
PUB. DATE
May 2007
SOURCE
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p74
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on a study on the relative efficacy and tolerability of vildagliptin and rosiglitazone in patients with type 2 diabetes. He asserted that the measurement of hemoglobin level in patients with type 2 diabetes may not capture all the benefits. Thus, large trials of sufficient duration must take place before incorporation of these drugs into practice. He claimed that gliptins could reduce hemoglobin levels but with uncertainty regarding its harms and long-term benefits.
ACCESSION #
25169126

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics